[Chemotherapy of carcinoma of the respiratory and digestive tracts with vindesine sulfate. Phase II clinical trial].
Results of a phase II clinical trial of vindesine sulfate in differentiated carcinoma of the upper respiratory and digestive tracts demonstrated good efficacy, with 6 objective responses in the 14 patients with interpretable reports several toxic reactions were observed, three patients developing polyneuritis of the upper and lower limbs after doses of 33 to 40 mg of DVA. Hematologic toxicity was moderate and regressive.
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004067:Digestive System Neoplasms / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D012142:Respiratory Tract Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014751:Vindesine
D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D014751:Vindesine
Chimiothérapie des carcinomes des voies aérodigestives par le sulfate de vindésine. Essai thérapeutique phase II.